ArticleOncology and therapy2025

Shared Decision-Making for Advanced Renal Cell Carcinoma: Focus on Adverse Event Management of Axitinib Plus IO: A Vodcast.

Edwin M Posadas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.